Genotype-guided alternatives to clopidogrel, like ticagrelor and cilostazol, significantly lower recurrent stroke risk in CYP2C19 loss-of-function carriers in Asia.
Does genotype-guided antiplatelet therapy reduce recurrent stroke risk in Asian patients requiring secondary stroke prevention compared to standard clopidogrel?
Genotype-guided antiplatelet therapy is essential for secondary stroke prevention in Asia due to the high prevalence of CYP2C19 loss-of-function alleles that reduce clopidogrel efficacy.
Stroke is a leading cause of death and disability globally, with Asia disproportionately affected. A critical barrier to effective secondary prevention is the high prevalence of CYP2C19 loss-of-function alleles, present in almost 75% of South and East Asians, which reduce clopidogrel efficacy. Evidence from trials, including CHANCE-2 (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events), shows that genotype-guided alternatives, including ticagrelor and cilostazol, substantially lower recurrent stroke risk in loss-of-function carriers. Yet, clinical adoption remains limited by insufficient genetic testing infrastructure, cost, guideline gaps, and clinician training. Despite these challenges, genotype-guided therapy is both feasible and cost-effective, with the potential to reduce recurrent strokes, disability, and healthcare burden. Urgent action is required to implement precision antiplatelet strategies, update guidelines, and ensure equitable access, making pharmacogenomics a central component of stroke care in Asia.
Raheja et al. (2025) studied this question. Genotype-guided alternatives to clopidogrel, like ticagrelor and cilostazol, significantly lower recurrent stroke risk in CYP2C19 loss-of-function carriers in Asia.